MEDV BLOWFISH and SONA - Big Difference If we track the share price of Sona Nanotech and their announcement of a saliva test that failed clinical trials in stage 2, we see a real opporuntiy for Medivolve. "I mean, If the share price for Sona can touch a 1 Billion dollar evaluation pre-stage 2, imagine what Blowfish, a multi-viral device could do". "World wide sales of this device could touch tens, even hundreds of millions per year". News related to scond phase testing will likely take some time, however, late June or early July would be my best guesstimate.
With the second phase of testing now in progress, BlowFISH is currently on the right track to seek EUA approval from the FDA.
“BlowFISH’s detection of the COVID-19 virus brings us one significant step closer to changing the future of diagnostics for not only COVID-19, but for a wide range of respiratory illnesses,” said Dr. Pirouz Kavehpour, UCLA Professor and Marvel Diagnostics Co-Founder. “We are moving forward with urgency through proof-of-concept clinical trials, as these studies are a critical next step in making respiratory testing more comfortable, convenient and accessible for all...one breath at a time.”